Navigation Links
Telik Regains Compliance With Minimum Bid Price Requirement
Date:4/17/2012

PALO ALTO, Calif., April 17, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today announced that it has received from The Nasdaq Stock Market notification that Telik has regained compliance with the minimum bid price rule for continued listing on The Nasdaq Capital Market because the bid price of Telik's common stock has closed at $1.00 per share or greater for at least 10 consecutive business days.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candidate is Telintra®, a modified glutathione analog intended for the treatment of hematologic disorders including myelodysplastic syndrome; followed by Telcyta®, a cancer activated drug for the treatment of a variety of cancers.  Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP®, which enables the rapid and efficient discovery of small molecule drug candidates.  Additional information is available at www.telik.com.

TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks or registered trademarks of Telik, Inc.


'/>"/>
SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Telik Announces Fourth Quarter and 2011 Year End Financial Results and 2012 Financial Guidance
2. Telik Announces Presentation and Webcast at 14th Annual BIO CEO & Investor Conference
3. Telik Announces Telintra Clinical Presentations at the Annual Meeting of the American Society of Hematology
4. Telik Announces Third Quarter 2011 Financial Results
5. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
6. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
7. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
8. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
9. Telik Announces First Quarter 2011 Financial Results
10. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
11. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... LONDON , Jan. 19, 2017 ... 2022 Summary GlobalData,s new report, "Germany Cataract ... data on the Germany Cataract Surgery Devices market. The ... (in units) and average prices (USD) within market segements ... The report also provides company shares and distribution shares ...
(Date:1/19/2017)... 2017 The global immunomodulators market is ... according to a new study by Grand View ... predominantly driven by high R&D investments employed by ... of new and therapeutically advanced drugs. This is ... an unprecedented rate into the immunomodulators market hence ...
(Date:1/19/2017)... , Jan. 19, 2017 Report Details ... Market? Which areas are going to grow at the ... to 2026, assessing data, trends, opportunities and prospects. ... Discover the most lucrative areas in the industry and ... assess forecasted sales across the all the major categories ...
Breaking Medicine Technology:
(Date:1/19/2017)... ... January 19, 2017 , ... WholeHealth is announcing their participation ... Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus will be present Saturday and Sunday in ... program. , “We know it’s easy to get carried away when you’re ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... CTMS, which provides a modern CTMS workflow designed to seamlessly integrate and streamline ... been condensed to a single page, maximizing usability and improving efficiency significantly for ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
(Date:1/19/2017)... , ... January 19, 2017 , ... Attorney Robert ... fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. Each year, ... one of those children. James saw firsthand the effect of the critical funding gap ...
Breaking Medicine News(10 mins):